Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner

BEIJING - Despite being hit by a succession of vaccine scandals and resulting public fears of domestically produced biologics, China's leading vaccine developer could ultimately emerge as a more powerful player due to its sterling reputation in a field of tarnished competitors